ArticleBMC infectious diseases2026
ACOD1 expression in patients with sepsis: an exploratory study of associations with disease severity and immune signatures.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Sepsis is a life-threatening condition caused by a dysregulated host response to infection, and its pathogenesis is closely linked to immune dysregulation and inflammation. Aconitate decarboxylase 1 (ACOD1) and its metabolite itaconate are key regulators of immunometabolism, but their roles in modulating immune cell function and maintaining immune homeostasis in sepsis have not been fully elucidated. In the GSE185263 dataset, we found that ACOD1 mRNA expression was significantly elevated in the blood of sepsis patients compared to controls. Functional enrichment (GO/KEGG), gene set enrichment (GSEA), and immune-cell infiltration analyses showed that higher ACOD1 expression was associated with inflammatory and interferon-related pathways and greater inferred M1 macrophage infiltration. Protein–protein interaction network analysis linked ACOD1 to proteins involved in glucose and amino acid metabolism, providing hypothesis-generating insight into its potential metabolic context. We subsequently examined ACOD1 mRNA expression in a prospective, single-center cohort consisting of 35 ICU patients with sepsis and 10 healthy controls. ACOD1 was up-regulated in sepsis and positively correlated with SOFA, APACHE II and DIC scores, and higher expression was associated with lower 28-day survival. In this exploratory cohort, ACOD1 emerged as a candidate biomarker reflecting sepsis severity, immune status and prognosis, but its performance requires validation in larger multi-center studies.Clinical trial number Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.